Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.43−0.00 (-0.95%)
Close on Nov 13, 2026Market cap $80.59MP/E –Yield –
Neumora Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Neumora Therapeutics's total debt was $112.91M at Jun 30, 2026. For fiscal 2025 it was $114.53M.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.53M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $112.91M | +186.2% |
| Q1 FY2026 | Mar 31, 2026 | $112.96M | – |
| Q4 FY2025 | Dec 31, 2025 | $114.53M | – |
| Q3 FY2025 | Sep 30, 2025 | $39.56M | – |
| Q2 FY2025 | Jun 30, 2025 | $39.45M | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
See a number that looks wrong?